References
- Global Initiative for Asthma (GINA) Report. Global strategy for asthma management and prevention. Updated 2010. Available at: http://www.ginasthma.org. Accessed 11 July, 2011.
- Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigator Group. Can guideline defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170(8):836–844.
- EMEA Xolair_SmPC. Available at: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf. Accessed July 22, 2011.
- Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
- Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005–1015.
- Figliomeni M, Kianifard F, Meng X.A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma. J Allergy Clin Immunol 2011; 127(2 Suppl. 1):AB84.
- Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302–308.
- Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005; 99:11–19.
- Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103:1098–1113.
- Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102:71–76.
- Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103:1725–1731.
- Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009; 103:1633–1642.
- Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010; 104:1410–1416.
- Schatz M, Eisner MD, Zazzali J, Bradley MS, Miller MK, Am J. Longitudinal impact of omalizumab on asthma control over two years. Resp Crit Care Med 2011; 183:A4495.
- Guía Española para el Manejo del Asma (GEMA). Editorial: Luzan 5 Madrid, 2009. Available at: http://www.gemasma.com. Accessed 11 July, 2011.
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59–65.
- Price D. The use of omalizumab in asthma. Prim Care Respir J 2008; 17:62–72.
- Global Initiative for Asthma (GINA) Report. Global strategy for asthma management and prevention. NHLBI/WHO workshop report 2006. Available at: http://www.ginasthma.com. Accessed 21 June, 2011.
- Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120:1223–1225.
- Pérez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O, Ausin P, Borderías L, Fernández C, Granel C, Pérez-Pimiento A, Rubio M. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011; 66(6):539–540.
- Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 2010; 10(3):194–201.
- Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116(5):970–975.